As a psychiatric provider, can I prescribe a GLP-1 receptor agonist (e.g., semaglutide) for a patient who reports having an eating disorder, or does my scope of practice prohibit this?

No, a patient simply stating they have an eating disorder is not sufficient justification for you to prescribe a GLP-1 receptor agonist as a psychiatric provider.

Scope of Practice and Clinical Appropriateness

You should not prescribe GLP-1 agonists for eating disorders in psychiatric practice, as these medications are FDA-approved only for type 2 diabetes and obesity management, not for eating disorder treatment 1. Your initial instinct about scope of practice limitations is correct—GLP-1 prescribing typically falls outside standard psychiatric practice unless you have specific training and credentialing in metabolic/obesity medicine.

Why This Is Problematic

Lack of Evidence for Eating Disorder Treatment

Current research shows insufficient evidence to support using GLP-1 agonists to treat eating disorder symptoms 2. While preliminary studies suggest potential benefit for binge eating disorder specifically 3, the evidence base remains limited with significant design flaws 2. One retrospective study showed reduced Binge Eating Scale scores with semaglutide 3, but this is far from establishing standard of care.

Potential Harms in Eating Disorder Populations

GLP-1 agonists may actually worsen or trigger eating disorder pathology 2, 4:

• Appetite suppression could reinforce restrictive eating patterns, particularly dangerous in anorexia nervosa or restrictive subtypes
• Rapid weight loss may disrupt body perception and intensify body image disturbance 4
• The medications could maintain or exacerbate rigid control and perfectionistic traits common in eating disorders 4
• Social media discourse around these medications glamorizes thinness and intensifies weight stigma 4

Psychiatric Safety Concerns

Recent pharmacovigilance data raises red flags:

• Semaglutide shows disproportionate reporting of eating disorders (aROR 4.17-6.80), depressed mood disorders (aROR 1.70), and suicidality (aROR 1.45) 5
• New-onset depression occurred in 9.0% and anxiety in 8.7% of patients in one retrospective review, with mean latencies of 15-16 months 6
• These signals emerged primarily post-marketing after approval for weight management, not in original diabetes trials 5

What You Should Do Instead

Conduct Proper Eating Disorder Assessment

The 2023 APA Eating Disorder Guidelines mandate comprehensive evaluation before any treatment 7:

• Document specific eating disorder diagnosis (anorexia nervosa, bulimia nervosa, binge eating disorder, ARFID, etc.)
• Quantify eating behaviors: frequency/intensity of restriction, binge episodes, purging, compensatory behaviors
• Assess weight history: maximum, minimum, recent changes
• Measure vital signs including orthostatic changes, which indicate medical instability
• Order labs: CBC, comprehensive metabolic panel, ECG if restrictive eating or severe purging present
• Evaluate percentage of time preoccupied with food, weight, body shape
• Screen for co-occurring psychiatric conditions

Provide Evidence-Based Eating Disorder Treatment

The APA recommends eating disorder-focused psychotherapy as first-line treatment 7:

• For adults with anorexia nervosa: eating disorder-focused psychotherapy targeting normalization of eating, weight restoration, and psychological aspects
• For adolescents/emerging adults with anorexia: family-based treatment
• For binge eating disorder: consider lisdexamfetamine (the only FDA-approved medication for BED) or topiramate off-label 8

Refer Appropriately

Eating disorders require multidisciplinary treatment incorporating medical, psychiatric, psychological, and nutritional expertise 7. If the patient needs weight management:

• Refer to primary care, endocrinology, or obesity medicine for GLP-1 evaluation
• Ensure eating disorder treatment is established and stable first
• Coordinate care to monitor for worsening eating disorder symptoms if GLP-1s are prescribed by another provider

Critical Pitfall to Avoid

Do not prescribe GLP-1 agonists simply because a patient requests them for weight loss while mentioning an eating disorder history. This represents a dangerous intersection where:

1. The medication is outside your scope of practice
2. The eating disorder may be active and undiagnosed/undertreated
3. The medication could worsen the underlying psychiatric condition
4. You lack the medical infrastructure to monitor metabolic parameters and complications

The fact that she's specifically requesting this medication raises concern about possible eating disorder-driven weight control behavior, which the APA guidelines specifically identify as requiring assessment 7.

Your responsibility is to properly diagnose and treat the eating disorder through evidence-based psychiatric interventions, not to prescribe weight loss medications that could perpetuate the pathology 2, 4.